Live
Suven Life Sciences has been granted two product patents one by Australia and one by Singapore, corresponding to a new chemical entity (NCE) for treating disorders related with neurodegenerative diseases.
Theses patents are valid till 2034. Venkat Jasti, Suven Life CEO stated, “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
Further, the granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, ADHD, Parkinson’s, Huntington’s disease and schizophrenia.
